The Daily Biotech Pulse: Setback For NRx Pharma’s COVID Study, Fast Track Tag For Pfizer’s NASH Combo Therapy, Reata’s Ataxia Drug In FDA Review
Here's a roundup of top developments in the biotech space over the last 24 hours:
Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?
Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) determined that the evaluation…
NRX Pharmaceuticals Q1 EPS $(0.21) Up From $(0.71) YoY
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.21) per share. This is a 70.42 percent increase over losses of $(0.71) per share from the same period last year.
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell
• AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
